Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals solid financial performance, optimistic guidance, and strategic initiatives that indicate potential growth. The Q&A section highlights positive trends such as increased proposal volumes, AI's potential in drug discovery, and improving margins. Although there are some uncertainties, like the sluggish demand from smaller biotechs, the overall sentiment is positive due to strong financial metrics, optimistic guidance, and strategic focus on M&A and capital allocation. Despite the lack of market cap data, these factors suggest a likely positive stock price movement in the short term.
Key Financial Performance
Revenue Revenue declined 1.5% on an organic basis year-over-year. The decline was attributed to lower revenue for small models in North America and for non-human primates (NHPs) due to the timing of shipments. However, there was solid demand for small models in China from mid-tier biotech and CRO clients.
Non-GAAP Operating Margin The non-GAAP operating margin declined 280 basis points to 16.3% year-over-year. This was largely driven by higher stock compensation expense, NHP study-related costs in the DSA segment, and lower NHP revenue in the RMS segment.
Non-GAAP Earnings Per Share (EPS) Non-GAAP EPS declined 12% to $2.06 year-over-year. The decline was primarily due to the lower operating margin.
RMS Revenue RMS revenue declined 5.5% organically year-over-year. This was driven by lower sales of small and large models as well as research model services. Small models revenue was pressured by lower volume in North America, partially offset by a solid increase in China volume. Large model revenue was affected by the timing of NHP shipments.
DSA Revenue DSA revenue declined 1.4% organically year-over-year. The decline was due to lower revenue for discovery services, although revenue for Safety Assessment services remained stable.
Manufacturing Revenue Manufacturing revenue increased 2.9% organically year-over-year. This growth was driven by strong demand for Microbial Solutions, particularly the Endosafe and Celsis manufacturing quality control testing platforms.
Net Book-to-Bill Ratio The net book-to-bill ratio for the DSA segment was 1.04x in the first quarter, indicating solid demand. Net bookings totaled $622 million, driven by continued strength from small and mid-sized biotech client bases.
Free Cash Flow Free cash flow was negative $15 million in the first quarter, a reduction of $127 million compared to the prior year period. This decline was mainly driven by higher performance-based cash bonus payments for 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Pathway to Purpose Strategy: Introduced a new strategic framework focusing on modernizing operations, enhancing scientific capabilities, and client-centric approaches.
Apollo Cloud-Based Platform: Expanded its scope to include study design, CRADL, and manufacturing businesses, enhancing client engagement and operational efficiency.
NAMs (New Approach Methodologies): Acquired PathoQuest to advance in vitro next-generation sequencing for biologics quality control testing.
Geographic Expansion: Strengthened presence in Asia, particularly through the acquisition of K.F. Cambodia and Noveprim to secure non-human primates supply chain.
Client-Centric Approach: Focused on deepening relationships with biopharmaceutical clients and leveraging AI for sales and operational improvements.
Cost Savings Initiatives: Achieved $100 million in incremental cost savings in 2026, with a cumulative $300 million from past years' actions.
Operational Modernization: Streamlined processes and embraced technology like AI and lab automation to enhance efficiency and data insights.
Portfolio Refinement: Divested CDMO and Cell Solutions businesses and planned sale of European discovery sites to focus on core competencies.
AI and Virtual Control Groups: Leveraged AI for virtual control groups in safety assessment studies, reducing reliance on animal models.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Demand: Demand from small and mid-sized biotech clients declined in the first quarter, reflecting softer DSA booking activity last summer and constrained funding for early-stage and seed biotech companies. This could impact revenue trends in the near term.
Government Funding: Uncertainty and funding pressures at the NIH have modestly impacted client spending levels, which could affect revenue from global academic and government clients.
Operational Efficiency: The company faces challenges in achieving additional cost savings and operational efficiencies despite already generating significant savings. Further modernization and streamlining efforts are required to meet future margin expansion goals.
Supply Chain: The timing of shipments for non-human primates (NHPs) has caused revenue declines in the RMS segment. Additionally, higher NHP sourcing costs have impacted margins in the DSA segment.
Regulatory Compliance: Maintaining rigorous oversight on animal welfare, biosecurity, and regulatory compliance remains a challenge as the company expands its operations and capabilities.
Economic Environment: The constrained funding environment for early-stage biotech companies and the broader economic uncertainties could limit growth opportunities and client spending.
Divestitures and Acquisitions: The company is undergoing significant portfolio changes, including divestitures and acquisitions, which could pose integration risks and impact short-term operational stability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects organic revenue to decline by 0.5% to 1.5% for the full year 2026, with a return to organic revenue growth in the second half of the year. Reported revenue is expected to decline by 4.0% to 5.5% due to divestitures and less favorable FX rates.
Operating Margin: Operating margin is expected to improve by approximately 120 to 150 basis points in 2026, with significant improvement in the second half of the year. The second half operating margin is projected to be over 500 basis points higher than the first half.
Earnings Per Share (EPS): Non-GAAP EPS is projected to grow by 5% to 10% in 2026, reaching $10.80 to $11.30. Second-quarter EPS is expected to improve by at least 30% sequentially from the first quarter.
Cost Savings: The company aims to achieve over $100 million in incremental cost savings in 2026, with cumulative annualized savings exceeding $300 million from actions taken in recent years.
Capital Deployment: The company plans to take a balanced approach to capital deployment, including M&A, organic investments, stock repurchases, and debt repayment. Approximately $200 million in shares were repurchased in the first quarter under a $1 billion authorization.
Divestitures and Acquisitions: The company completed the divestiture of the CDMO and Cell Solutions businesses and plans to finalize the sale of certain European Discovery sites in May. These actions, along with the acquisition of Charles River Cambodia, are expected to drive margin expansion and strengthen core capabilities.
Market Trends: Biopharma demand is stabilizing, with pockets of improvement among global biopharmaceutical and small to mid-sized biotechnology clients. Revenue trends from biotech clients are expected to improve in upcoming quarters due to a healthier funding environment.
Technology and AI: The company is leveraging AI and machine learning to enhance operational efficiency, client engagement, and scientific capabilities. AI is expected to support R&D efforts, leading to faster drug discovery and increased IND approvals over the next several years.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Repurchase Authorization: Repurchased approximately $200 million in shares under the $1 billion stock repurchase authorization approved last October.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the typical seasonality in terms of the demand cycle and provide updates on demand conversations with clients?
A:The CEO explained that several business segments experience seasonality, such as the DSA business, biologics testing, and microbial business. For example, DSA bookings and proposals start slow early in the year due to budget approvals and reprioritization. Biologics testing sees reduced activity during Christmas due to manufacturing shutdowns. Demand environment shows cautious optimism with biotech funding improving and pharma clients focusing on speeding up programs rather than reprioritization.
Q:Can you provide more color on proposal volumes year-over-year and sequentially, and how they trended among client segments?
A:Proposal volumes were up in high single digits year-over-year for both global biopharmaceutical and biotech segments. Sequentially, proposals have increased for three consecutive quarters, indicating positive trends and client readiness to restart work.
Q:Are AI investments in drug discovery leading to more preclinical testing, or is this a future trend?
A:The CEO expressed optimism about AI's potential impact on the industry. Currently, AI-assisted drug discovery programs are limited, but they generally work on multiple programs simultaneously. While it's early days, AI is expected to lower early discovery costs and reinvestment, potentially increasing preclinical testing in the future.
Q:Can you discuss the margin outlook for the second half of the year and beyond, including the impact of acquisitions and divestitures?
A:Margins are expected to improve significantly in the second half of the year, with a 500 basis point increase driven by acquisitions, divestitures, cost savings initiatives, and timing of NHP shipments. For 2027, acquisitions and divestitures are expected to contribute $0.50 to $0.55 of accretion compared to 2026.
Q:What is the outlook for small and mid-sized biotech clients, especially in light of recent funding improvements?
A:Larger biotech companies benefiting from IPOs and funding are showing increased demand, while smaller, early-stage biotechs remain sluggish. Confidence in funding is gradually improving, but demand in certain areas like the CRADL business unit is still below expectations.
Q:Are there any incremental ambitions for acquisitions or divestitures, and what are the capital allocation priorities?
A:The company will continue to review its businesses for synergies and profitability, potentially leading to site consolidations or divestitures. M&A remains a focus, with a clear roadmap for investments. Capital allocation priorities include organic investments, partnerships, and share buybacks.
Q:What is the current revenue contribution from NAMs, and how has it been impacted by recent acquisitions and divestitures?
A:NAMs revenue was previously estimated at $200 million annually. Recent acquisitions like PathoQuest have added to this, while divestitures have reduced it slightly. The company retains roughly two-thirds of the NAMs revenue and continues to focus on regulated spaces.
Q:What are the conversion rates and decision-making velocity for increasing proposal volumes?
A:Conversion rates have accelerated compared to the COVID period. Discussions to bookings now take 1-2 quarters, with some cases seeing revenue within the same quarter. This acceleration improves backlog quality and reduces cancellations.
Q:Are global pharma accounts increasing their preclinical budgets, and how are bookings trending?
A:Global pharma bookings were below last year's exceptional levels but are considered adequate. Proposals are up, indicating potential future bookings growth. Pharma clients are focusing on moving more programs into INDs and clinics, which may imply increased preclinical budgets.
Q:How does biotech M&A activity impact access to biotech wallet share?
A:Biotech M&A generally does not negatively impact wallet share. The company often works with small biotechs before acquisition and retains work post-acquisition. Larger pharma acquisitions may provide access to new programs, and the company focuses on increasing wallet share through client-centric initiatives.
Q:What is the margin impact of internal NHP supply, and when will it fully benefit Charles River?
A:The margin impact of internal NHP supply will be more evident in Q4, with improvements expected as higher NHP costs are worked through. Transitioning external NHP supply to internal use will occur over the next few years.
Q:What is the competitive landscape in Asia, and how does it impact the business?
A:Outsourcing to lower-cost countries like China and India is increasing for early-stage routine work. However, complex and regulated work remains largely outsourced to Charles River. The company is evaluating opportunities to expand in China while monitoring geopolitical risks.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the long-term margin framework for the DSA segment post-NHP acquisitions, as well as precise numbers for cost savings in 2027 and 2028. Additionally, they did not elaborate on the exact timeline for transitioning external NHP supply to internal use.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
Apollo
Assessment service
Birgit Girshick
CDMO Cell
CDMO divestiture
CDMO rate
CEO
CFO
Cambodia
Discovery site
European Discovery
KF
NHP study
VCG
approach capital
capital deployment
class portfolio
client experience
client speed
core capability
deployment investment
discovery service
efficiency
effort
foundation
funding environment
industry
life
margin expansion
margin headwind
margin improvement
opportunity
pathway purpose
reminder
shareholder value
solution
stock compensation
week
world
CRL Transcript
Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary reveals solid financial performance, optimistic guidance, and strategic initiatives that indicate potential growth. The Q&A section highlights positive trends such as increased proposal volumes, AI's potential in drug discovery, and improving margins. Although there are some uncertainties, like the sluggish demand from smaller biotechs, the overall sentiment is positive due to strong financial metrics, optimistic guidance, and strategic focus on M&A and capital allocation. Despite the lack of market cap data, these factors suggest a likely positive stock price movement in the short term.
Charles River Laboratories International, Inc. (CRL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Charles River Laboratories International, Inc. (CRL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-3
Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript
Unknown2-18
The earnings call presents a mixed picture: stable financial guidance with flat to slightly declining revenue and margins, countered by optimistic long-term guidance and strategic divestitures. The Q&A section reveals management's confidence in future demand and strategic initiatives, yet there are uncertainties like DSA demand volatility and unclear expansion details. The positive aspects are balanced by cautious market conditions and flat short-term performance, leading to a neutral sentiment.
CRL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
